A Study Evaluating the Safety and Efficacy of AVE5530 (4 Weeks) in Patients With Mild to Moderate Hypercholesterolemia
Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the effect of AVE5530 on LDL-C levels over a
period of 4 weeks. The secondary objectives are to assess the effects of AVE5530 on other
lipid plasma levels and the safety and tolerability of AVE5530.